Most recently Co-Chief Executive Officer, Co-Chairman and Co-Founder of Amneal Pharmaceuticals, Chirag is now a Co-Chairman of the Board of Directors. Chirag’s lifelong drive and constant desire to discover “what’s next” has helped grow Amneal from humble beginnings to an emerging global presence. Chirag is the recipient of several industry honors including the 2011 Ernst & Young National Entrepreneur of the Year Life Sciences Award® and supports various philanthropic and charitable causes both in the U.S. and abroad. Chirag and his wife, Priti, established the Niswarth Children Foundation in 2013, with the goal of bringing fresh water, sanitation, sustenance and education to over one million underprivileged children in India. Chirag serves on the boards of the Liberty Science Center®, the Art of Living Foundation®, New Jersey City University Foundation and the Family Reach Foundation. Chirag received his bachelor’s degree in commerce from H.A. College of Commerce, India and another Bachelor’s degree in business administration from New Jersey City University. He also received an honorary doctorate degree from New Jersey City University.
Most recently Co-Chief Executive Officer, Co-Chairman and Co-Founder of Amneal Pharmaceuticals, Chintu is now a Co-Chairman of the Board of Directors. Chintu‘s vision of building a pharmaceutical company based upon quality and integrity led to Amneal’s founding. His passion for excellence in R&D and developing high quality, affordable medicines has been deeply rooted since his days as a student of pharmacy. Chintu has more than 20 years of distinguished experience within the industry, beginning with his career at Eckerd Pharmacy. He has been recognized by his peers on numerous occasions, including the 2011 Ernst & Young National Entrepreneur of the Year Life Sciences Award®. His commitment to business growth and philanthropy is evident in the many organizations Amneal supports. Chintu has been a featured speaker at the Hauppauge Industrial Association of New York and serves on the boards of the Long Island Association and the Make-a-Wish Foundation®. Chintu, along with his wife, Falguni, created the Irada Foundation, focusing on health and education issues. Chintu holds a Bachelor’s degree in pharmacy from Rutgers College of Pharmacy.
Paul M. BisaroExecutive Chairman
Paul Bisaro is Executive Chairman of Amneal Pharmaceuticals, Inc. Mr. Bisaro was named Executive Chairman following Amneal’s merger with Impax Laboratories, Inc. in May 2018.
Previously, Mr. Bisaro served as President and Chief Executive Officer and a member of the Impax Laboratories Board of Directors since March 2017. He is an accomplished global business leader with more than 25 years of generic and branded pharmaceutical experience, and an exceptional track record of driving company growth through operational execution and corporate transformation.
Prior to joining Impax, Mr. Bisaro served as Executive Chairman of Allergan, plc1 from July 2014 to November 2016, as President and CEO of Actavis, plc1 from October 2012 to July 2014, and as President and CEO of Watson Pharmaceuticals, Inc.1 from September 2007 to October 2012.
He also previously served as President, Chief Operating Officer and a member of the Board of Directors of Barr Pharmaceuticals, Inc., a global specialty pharmaceutical company (Barr), from 1999 to 2007. Between 1992 and 1999, Mr. Bisaro served as General Counsel of Barr, and from 1997 to 1999, served in various additional executive leadership capacities.
Prior to joining Barr, he was associated with the law firm Winston & Strawn and a predecessor firm,
Bishop, Cook, Purcell and Reynolds, from 1989 to 1992. He also served as a Senior Consultant with
Arthur Andersen & Co.
Mr. Bisaro currently serves on the Board of Directors of Zoetis, Inc. and on the Board of Visitors of the Catholic University of America’s Columbus School of Law. He also served as Chairman of the Board of the Generic Pharmaceutical Association (GPhA, now Association of Accessible Medicines [AAM]) in 2010 and 2011.
Mr. Bisaro holds an undergraduate degree in General Studies from the University of Michigan and a Juris Doctor from Catholic University of America in Washington, D.C.
1. Watson Pharmaceuticals, Inc. (founded in 1984) changed its name to Actavis, plc following the merger of the two companies in October 2012. Actavis, plc subsequently changed its name to Allergan, plc following the merger of the two companies in March 2015.
Robert StewartPresident and Chief Executive Officer
Robert Stewart is President and Chief Executive Officer of Amneal Pharmaceuticals, Inc. Mr. Stewart was named President and CEO following Amneal’s merger with Impax Laboratories, Inc. in May 2018.
Previously, Mr. Stewart served as Chief Operating Officer of Allergan plc. He has more than 22 years of experience in global brand and generic pharmaceutical leadership, including expertise in M&A integration, operational excellence, supply chain, R&D, quality and manufacturing management.
Prior to his appointment as Chief Operating Officer of Allergan in May 2016, Mr. Stewart served executive leadership roles of increasing responsibility, including as President, Generics and Global Operations from March 2015 to May 2016; Chief Operating Officer from July 2014 to March 2015; and President, Global Operations, from August 2010 to July 2014. He joined Allergan (then Watson) in November 2009 as Senior Vice President, Global Operations. Before joining Watson, Rob held various senior leadership roles with Abbott Laboratories, Inc. (1995 through 2009) as well as Hoffman La-Roche Inc.
Mr. Stewart currently serves as Vice Chair of the Board of The Association for Accessible Medicines (AAM). He has also served as a Member of the Board of the National Association of Manufacturers (NAM) since September 2016, and a member of the Fairleigh Dickinson University Board of Trustees since June 2017.
Mr. Stewart holds a Bachelor’s degree in Business Management and Finance from Fairleigh Dickinson University.
Robert L. BurrLead Independent Director
Robert L. Burr served as Chairman of the Impax Laboratories, Inc. board from 2008 until the completion of the combination of Impax and Amneal; and having served as an independent director of Impax since 2001.Bob has been a self-employed investment manager since May 2008. Bob was employed by J.P. Morgan Chase & Co. and associated entities from 1995 to May 2008, at which time he resigned his position as Managing Partner of the Fleming US Discovery III Funds. From 1992 to 1995, Bob was head of Private Equity at the investment banking firm Kidder, Peabody & Co., Inc. Prior to that time, Bob served as the Managing General Partner of Morgan Stanley Ventures and General Partner of Morgan Stanley Venture Capital Fund I, L.P. and was a corporate lending officer with Citibank, N.A. Bob received an MBA from Columbia University and a BA from Stanford University. Bob’s financial acumen and his extensive knowledge of capital markets represent a valuable resource to the board in the assessment of our capital and liquidity needs. In addition, his venture capital and private equity investment experience gives Bob the leadership and consensus-building skills to guide the board on a variety of matters, including compensation, corporate governance and risk assessment.
Emily Peterson AlvaDirector
Emily Peterson Alva is a financial, strategic and business advisor to senior executives, founders and corporate boards of directors, and has focused on private company advisory projects and family office investing since 2013. Prior to this time, Ms. Alva spent more than 15 years at Lazard as a senior Mergers & Acquisitions investment banker advising industry leading companies. Ms. Alva’s extensive advisory and transaction work covers multiple industries with a primary sector focus and expertise in Healthcare. While at Lazard, Ms. Alva held leadership roles, both with clients and internally. She advised some of Lazard’s most important clients over many years, and was one of the youngest bankers promoted to Managing Director at the firm. During her Lazard tenure, Ms. Alva was selected for the Council on Foreign Relations’ Corporate Leaders Program, which recognizes accomplished professionals on a senior management track and links business leaders with decision makers in government and academia. Prior to joining Lazard, Ms. Alva worked at a development stage company focused on engineering-based solutions to improve industrial waste processing systems. More recently, Ms. Alva has served as a Board Member and Treasurer for the Alumnae Board of Directors of Barnard College. Ms. Alva received a B.A. in Economics from Barnard College, Columbia University.
J. Kevin BuchiDirector
Kevin Buchi served as Impax’s Interim President and Chief Executive Officer from December 2016 until March 27, 2017 and as member of the Impax board from November 2016 until the completion of the combination of Impax and Amneal. From August 2013 to December 2016, Mr. Buchi served as President and Chief Executive Officer and member of the board of directors of TetraLogic Pharmaceuticals Corporation (formerly NASDAQ: TLOG), a biopharmaceutical company (“TetraLogic Pharmaceuticals”), whose assets were subsequently acquired by Medivir AB in December 2016. Prior to TetraLogic Pharmaceuticals, Mr. Buchi served as Corporate Vice President, Global Branded Products of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), from October 2011 to May 2012. Prior to Teva, Mr. Buchi served as Chief Executive Officer of Cephalon, Inc. (formerly NASDAQ: CEPH), which was subsequently acquired by Teva, from December 2010 to October 2011, and held various positions at Cephalon including Chief Operating Officer from January 2010 to December 2010 and Chief Financial Officer from 1996 to 2009. Since April 2013, he has served as a director and member of the remuneration and nominating committee, and audit committee of the board of Benitec Biopharma Ltd. (NASDAQ: BNTC), a biotechnology company headquartered in Australia. Mr. Buchi has previously served on the board and committees of various pharmaceutical and biotechnology companies including: the board and the audit committee of EPIRUS Biopharmaceuticals, Inc. (formerly NASDAQ: EPRS) from June 2013 to July 2016; the board and compensation committee of Alexza Pharmaceuticals, Inc. (formerly NASDAQ: ALXA) from January 2013 to June 2016; the board and audit committee of Forward Pharma A/S (NASDAQ: FWP) from December 2012 to May 2016; the board and audit, compensation and nominating and corporate governance committees of Stemline Therapeutics, Inc. (NASDAQ: STML) from March 2012 to May 2016; and the board and audit committee of Meslobast Limited from 2010 to 2012. Mr. Buchi received his B.A. degree from Cornell University and a Masters of Management from the J.L. Kellogg Graduate School of Management at Northwestern University. Mr. Buchi’s extensive experience as a senior executive and board member in the pharmaceutical industry provides the board with unique insights into our business.
Jean Selden GreeneDirector
Jean Selden Greene is currently a Managing Director at Lazard and has served in a variety of roles at the firm since 1999. Throughout her tenure at Lazard, Ms. Green has lead financial and strategic advisory projects as part of Lazard’s Industrials group, with a focus on Capital Goods and Multi-Industry.
Among Ms. Greene’s recent representative transactions are the merger of Tyco with Johnson Controls, Xylem’s acquisition of Sensus, Dover’s acquisition of Wayne Fueling Systems and Pitney Bowes’s acquisition of Borderfree. Prior to joining Lazard, Ms. Greene was an Analyst at Smith Barney. Ms. Greene serves on the Board of Directors of Dress for Success, a global non-for-profit organization that promotes the economic independence of disadvantaged women. Ms. Greene received a B.A. from Wellesley College and an MBA from the University of Chicago. Ms. Greene’s deep understanding of finance, accounting and M&A will provide the Board with valuable perspective on strategy and corporate development.
Ted Nark has served as Managing Director of KRG Capital Partners, a Denver-based private equity fund currently investing a $2 billion fund, since 2007. In that role, Mr. Nark has led the identification, negotiation and due diligence of new acquisitions and has worked with portfolio companies and maintained relationships with limited partners. While at KRG, Mr. Nark has led the acquisition and successful monetization of companies including Convergint Technologies, Diversified Food Services and Petrochoice. From 2006 to 2007, Mr. Nark was a Partner at Leonard Green & Partners and from 2002 to 2006, he served as Chief Executive Officer and Chairman of the Board of White Cap Construction Supply, a Leonard Green-owned distributor of construction hardware, tools and materials to professional contractors in the United States. Previously, Mr. Nark served as Chief Executive Officer of Corporate Express Australia and Group President at Corporate Express Inc. Mr. Nark currently serves as Chairman of the Board of Convergint Technologies and Trafficware and is on the Board of Directors of Western Windows and The Maroon Group. Mr. Nark has previously served on the Boards of Corporate Express Australia, Fort Dearborn, White Cap Construction Supply, FTD, Leslies Pools, Gaiam, Real Goods Solar and Claim Jumper. Mr. Nark received a B.A. from Washington State University. Mr. Nark’s career in private equity and in executive positions will provide the Board with unique insight into management, challenges and opportunities.
Gautam Patel has served as Managing Director of Tarsadia Investments, a private investment firm based in Newport Beach, CA since 2012. In that role, Mr. Patel has led a team of investment professionals to identify, evaluate and execute principal equity investments across sectors including life sciences, financial services and technology. Prior to joining Tarsadia, Mr. Patel served as Managing Director at Lazard from 2008 to 2012, where he led financial and strategic advisory efforts in sectors including transportation and logistics, private equity, specialty pharmaceuticals and medical devices. Prior to that, Mr. Patel served in a variety of roles at Lazard from 1999 to 2008, including multiple restructuring, bankruptcy and corporate reorganization assignments. From 1994 to 1997, Mr. Patel was an Analyst at Donaldson, Lufkin & Jenrette (DLJ), where he worked on M&A as well as high-yield and equity financings. Mr. Patel is currently a Board Member of companies such as Amneal Pharmaceuticals, Adello Biologics, Asana Biosciences, LERETA and AIONX Antimicrobial Technologies, as well as Tarsadia Foundation. Mr. Patel received a B.A. from Claremont McKenna College, a B.S. from Harvey Mudd College, an M.S. from the London School of Economics (LSE) and an MBA from the University of Chicago. Mr. Patel’s extensive experience as an advisor, investor and operator in generics and the pharmaceutical industry broadly will provide the Board with insight regarding business development, strategic planning and operational management.
Dharmendra “DJ” RamaDirector
Dharmendra J. Rama has served as President and CEO of Auro Hotels, a privately held owner, developer and manager of upscale hotels, since 2017. Prior to the formation of Auro Hotels in 2017, Mr. Rama served as President of JHM Hotels, a predecessor company ranked as the eleventh largest hotel owner and developer as of 2016. From 1995 to 2011, Mr. Rama served as JHM’s Director of Operations. Prior to joining JHM, Mr. Rama held positions with Holiday Inn Worldwide, Interstate Hotels and Marriott Corporation. Mr. Rama currently serves on the Board of the American Hotel and Lodging Association (AHLA), and as co-chairman of the Owners Council of such board. Mr. Rama is a member of the Owners Advisory Councils of both Marriott International and Hyatt Hotels and Resorts. Mr. Rama currently serves on the Dean’s Advisory Board of the Cornell Hotel School, is President of the Cornell Hotel Society of South Carolina, and a member of the Board of Trustees of the Peace Center for the Performing Arts.
Mr. Rama received a B.S. from Johnson & Wales University, a Masters of Management in Hospitality from Cornell University, and is a 2016 graduate of the Owner/President Management (OPM) Program at Harvard Business School. Mr. Rama’s investment and management experience give him the leadership skills to guide the Board in multiple areas, including operations and strategy.
Peter R. TerreriDirector
Peter R. Terreri is President, Chief Executive Officer and director of CGM, Inc., a manufacturing company that he has owned and operated since 2000. Mr. Terreri served as a member of the Impax board from 2003 until the completion of the combination of Impax and Amneal. He previously served as Senior Vice President and Chief Financial Officer of Teva Pharmaceuticals USA from 1985 through 2000 and as an auditor at PricewaterhouseCoopers LLP from 1981 to 1984. Mr. Terreri received his B.S. in Accounting from Drexel University and has been a certified public accountant since 1981. Mr. Terreri’s more than 20 years of experience in the pharmaceutical industry provides the board with deep knowledge of operations and strategy. Additionally, his prior experience as Chief Financial Officer brings a deep understanding of accounting and risk management issues.
Janet S. VergisDirector
Janet S. Vergis has served as an Executive Advisor for private equity firms since January 2013, where she identifies and evaluates healthcare investment opportunities. Ms. Vergis served as a member of the Impax board from 2015 until the completion of the combination of Impax and Amneal. From January 2011 to August 2012, Ms. Vergis was the Chief Executive Officer of OraPharma, Inc., a specialty pharmaceutical company dedicated to oral health. From 2004 to 2009, she served as President of Janssen Pharmaceuticals LP, McNeil Pediatrics, Inc. and Ortho-McNeil Neurologics, Inc., subsidiaries of Johnson and Johnson (NYSE:JNJ). Ms. Vergis contributed to a number of Johnson & Johnson companies during her 21 years, holding positions of increasing responsibility in research and development, new product development, sales, and marketing. Since May 2014, Ms. Vergis has served as a director of the Board of Church & Dwight Co., Inc. (NYSE:CHD), a leading consumer and specialty products company, and is a member of the audit and governance committees. She has also served as a director and Chair of the Commercialization Committee for the Board of MedDay Pharmaceuticals, a privately held biotechnology company, since November 2016. Ms. Vergis previously served as a director of Lumara Health, a privately held pharmaceutical company (sold to AMAG Pharmaceuticals) from October 2013 to November 2014, and as a director of OraPharma from January 2011 to June 2012. Ms. Vergis received her M.S. degree in Physiology and her B.S. degree in Biology from The Pennsylvania State University. Her extensive experience in the pharmaceutical industry brings the board unique insights, particularly in the areas of new product development, sales, and marketing.